We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed the most recent trading day at $41.85, moving -1.67% from the previous trading session. This change lagged the S&P 500's 0.8% loss on the day. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 1.94%.
Coming into today, shares of the drugmaker had gained 10.03% in the past month. In that same time, the Medical sector gained 4.79%, while the S&P 500 gained 5.72%.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. On that day, PFE is projected to report earnings of $0.55 per share, which would represent no growth from the year-ago period. Meanwhile, our latest consensus estimate is calling for revenue of $12.88 billion, up 1.49% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.88 per share and revenue of $48.83 billion, which would represent changes of -2.37% and -5.64%, respectively, from the prior year.
Any recent changes to analyst estimates for PFE should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.63% lower. PFE is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note PFE's current valuation metrics, including its Forward P/E ratio of 14.8. This valuation marks a premium compared to its industry's average Forward P/E of 14.56.
It is also worth noting that PFE currently has a PEG ratio of 3.51. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. PFE's industry had an average PEG ratio of 2.2 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
Pfizer (PFE - Free Report) closed the most recent trading day at $41.85, moving -1.67% from the previous trading session. This change lagged the S&P 500's 0.8% loss on the day. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 1.94%.
Coming into today, shares of the drugmaker had gained 10.03% in the past month. In that same time, the Medical sector gained 4.79%, while the S&P 500 gained 5.72%.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. On that day, PFE is projected to report earnings of $0.55 per share, which would represent no growth from the year-ago period. Meanwhile, our latest consensus estimate is calling for revenue of $12.88 billion, up 1.49% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.88 per share and revenue of $48.83 billion, which would represent changes of -2.37% and -5.64%, respectively, from the prior year.
Any recent changes to analyst estimates for PFE should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.63% lower. PFE is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note PFE's current valuation metrics, including its Forward P/E ratio of 14.8. This valuation marks a premium compared to its industry's average Forward P/E of 14.56.
It is also worth noting that PFE currently has a PEG ratio of 3.51. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. PFE's industry had an average PEG ratio of 2.2 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.